HBC Hofseth Biocare

Hofseth Biocare ASA: Disclosure of large shareholding

Hofseth Biocare ASA: Disclosure of large shareholding

Reference is made to the stock exchange notice from Hofseth BioCare ASA dated 16 October 2020 regarding the private placement of NOK 200m (the "Private Placement").

As a consequence of the Private Placement the shareholding of funds managed by Bonafide (Bonafide Global Fish Fund, Bonafide Best Catches I, Deep Blue Ventures I, and Deep Blue Ventures III) falls below 20 % of the total shares outstanding in Hofseth BioCare ASA following the Private Placement. Bonafide funds controls a total of 69,302,732 shares in Hofseth BioCare ASA corresponding to approx. 19.53 % of total shares outstanding after the Private Placement.

This information is subject to the disclosure requirements pursuant to sections 4-3 and 5-12 of the Norwegian Securities Trading Act.

EN
16/10/2020

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Publication of the Prospectus – Start of the Subs...

Hofseth BioCare ASA: Publication of the Prospectus – Start of the Subscription Period for the Subsequent Offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placem...

6h / 4m 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Terms of the Subsequent Offering

Hofseth BioCare ASA: Terms of the Subsequent Offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company, ...

November 7, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: THIRD QUARTER 2025 FINANCIAL REPORT

Hofseth BioCare ASA: THIRD QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 54.9 million in the third quarter of 2025, compared to NOK 67.9 million in the same period last year. Net operating revenues were NOK 54.8 million, reflecting lower commodity prices and a weaker U.S. dollar during the quarter. EBITDA for the quarter was NOK -21.1 million (-21.0) and the operational EBITDA* amounted to NOK -12.9 million (-13.9m), excluding non-recurring and strategic development costs such as clinical studies, R&D expenses, and Berkåk project costs. Cash and cash equival...

November 7, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding (i) the completion of a private placement (the "Private Placement") of new shares in the Company the "Offer Shares"), the completion of which by delivery of Offer Shares in tranche 2 (the "T2 Offer Shares") is subject to, among other things, an extraordinary general meeting (the "EGM") resolving to issue the T2 Offer Shares in the Private Placement and (ii) a potential subsequent repair offering which i...

October 30, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Mandatory Notification of Trade

Hofseth BioCare ASA: Mandatory Notification of Trade Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company. In the Private Placement, Hofseth International AS was allocated 28,666,666 new shares at the subscription price of NOK 1.80. Please refer to the attached notification form for further information. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19. For furth...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch